BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 8967976)

  • 1. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
    Ilyin VI; Whittemore ER; Guastella J; Weber E; Woodward RM
    Mol Pharmacol; 1996 Dec; 50(6):1541-50. PubMed ID: 8967976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.
    Whittemore ER; Ilyin VI; Woodward RM
    J Pharmacol Exp Ther; 1997 Jul; 282(1):326-38. PubMed ID: 9223571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
    Williams K
    Mol Pharmacol; 1993 Oct; 44(4):851-9. PubMed ID: 7901753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine.
    Williams K
    Mol Pharmacol; 1994 Sep; 46(3):531-41. PubMed ID: 7935335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
    Buller AL; Larson HC; Morrisett RA; Monaghan DT
    Mol Pharmacol; 1995 Oct; 48(4):717-23. PubMed ID: 7476899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.
    Avenet P; LĂ©onardon J; Besnard F; Graham D; Frost J; Depoortere H; Langer SZ; Scatton B
    Eur J Pharmacol; 1996 Jan; 296(2):209-13. PubMed ID: 8838458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes.
    Coughenour LL; Cordon JJ
    J Pharmacol Exp Ther; 1997 Feb; 280(2):584-92. PubMed ID: 9023267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits.
    Williams K; Zappia AM; Pritchett DB; Shen YM; Molinoff PB
    Mol Pharmacol; 1994 May; 45(5):803-9. PubMed ID: 8190097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology.
    Monaghan DT; Larsen H
    J Pharmacol Exp Ther; 1997 Feb; 280(2):614-20. PubMed ID: 9023271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission.
    Frizelle PA; Chen PE; Wyllie DJ
    Mol Pharmacol; 2006 Sep; 70(3):1022-32. PubMed ID: 16778008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists.
    Tamiz AP; Cai SX; Zhou ZL; Yuen PW; Schelkun RM; Whittemore ER; Weber E; Woodward RM; Keana JF
    J Med Chem; 1999 Aug; 42(17):3412-20. PubMed ID: 10464027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.
    Coughenour LL; Barr BM
    J Pharmacol Exp Ther; 2001 Jan; 296(1):150-9. PubMed ID: 11123375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors.
    Tamiz AP; Whittemore ER; Zhou ZL; Huang JC; Drewe JA; Chen JC; Cai SX; Weber E; Woodward RM; Keana JF
    J Med Chem; 1998 Aug; 41(18):3499-506. PubMed ID: 9719603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors.
    Zhong J; Gribkoff VK; Molinoff PB
    Mol Pharmacol; 1996 Sep; 50(3):631-8. PubMed ID: 8794904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead inhibition of N-methyl-D-aspartate receptors containing NR2A, NR2C and NR2D subunits.
    Omelchenko IA; Nelson CS; Allen CN
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1458-64. PubMed ID: 9316859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells.
    Priestley T; Laughton P; Myers J; Le Bourdellés B; Kerby J; Whiting PJ
    Mol Pharmacol; 1995 Nov; 48(5):841-8. PubMed ID: 7476914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental decrease in ethanol inhibition of N-methyl-D-aspartate receptors in rat neocortical neurons: relation to the actions of ifenprodil.
    Lovinger DM
    J Pharmacol Exp Ther; 1995 Jul; 274(1):164-72. PubMed ID: 7616394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single channel analysis of a novel NMDA channel from Xenopus oocytes expressing recombinant NR1a, NR2A and NR2D subunits.
    Cheffings CM; Colquhoun D
    J Physiol; 2000 Aug; 526 Pt 3():481-91. PubMed ID: 10922001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors.
    Brimecombe JC; Gallagher MJ; Lynch DR; Aizenman E
    J Pharmacol Exp Ther; 1998 Aug; 286(2):627-34. PubMed ID: 9694913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.